Curify reached out to more than 100 sites, making participation much more accessible for patients all over the states. The simplicity of the inclusion/exclusion criteria — healthy volunteers, diverse community — contributed to Curify’s success. Because it was a COVID-19 vaccine trial, CEO Nazar Hembara said patients wanted to be part of something bigger than themselves.
Beyond the trial itself, Hembara said the Citeline Connect model aligns with Curify’s mission to bring new treatments to market faster. And to give more access to clinical trials, researchers, and pharmaceutical companies.
Being part of the community developing a COVID vaccine, it’s just really great. Everyone was really excited to be a part of it. Thanks to the Citeline Connect team for being so supportive, responding to our requests and providing feeback. We consider it a true partnership.
"We jumped in after the trial had begun, a little bit later than everyone else, and apparently we were one of the top three contributors. We were surprised. We just did what we could. We were happy to contribute to this COVID-19 trial," said Dan Wilde of ClinicalConnection.
The study required healthy volunteers. Wilde noted that ClinicalConnection recruits for a variety of different conditions and participants, including healthy volunteers.
We were looking for someone that had the reach that Citeline Connect had. We were looking for a different approach rather than just sending referrals directly to clinics, someone who had a direct connection to clinical trial sponsors. A more robust solution. It’s just a really slick platform. I enjoyed using it, and the team did as well. I liked the responsiveness and the data that the platform provides.
